Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study
2017 ◽
Vol 36
(9)
◽
pp. 2129-2134
◽
2019 ◽
Vol 27
(e1)
◽
pp. e30-e35
◽
2017 ◽
Vol 11
(suppl_1)
◽
pp. S312-S312
2020 ◽
Vol 45
(5)
◽
pp. 587-599
2018 ◽
Vol 1
(suppl_1)
◽
pp. 197-198
2006 ◽
Vol 67
(2)
◽
pp. 103-117
◽